Limiting AAA With Metformin (LIMIT) Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 314 participants.

Also called NCT04500756

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 314 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04500756
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04500756. Randomized; triple masking; primary purpose treatment. Start 2022-02-28 (actual); primary completion 2028-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Limiting AAA With Metformin (LIMIT) Trial
Acronym
LIMIT
Condition
Abdominal Aortic Aneurysm
Intervention (Drug)
Metformin
Intervention (Other)
Placebo
Lead sponsor
Stanford University (class: other)
Collaborator
Kaiser Permanente (class: other)
Collaborator
VA Palo Alto Health Care System (class: US federal agency)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct04500756
Content hash
43b58f85fd8d20baf8d06e20c5e4d2da6237cfbc2157554bedd4e005a2009fc6